Clinical trial NCT04524975: А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding, Pilot Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anxiety Disorder Generalized
Keywords: Anti-Anxiety Agents
Anxiety Disorder Generalized
Lead sponsor: ChemRar Research and Development Institute, LLC
Sponsor class: INDUSTRY
First posted: 2020-08-24
Enrollment: 129
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging pilot study to assess the efficacy and safety of CD-008-0045 in patients with GAD. The primary study objective is to select the dosage regimen for CD-008-0045 (20 mg BID or TID) based on preliminary assessment of its efficacy versus placebo according to frequency of treatment response at Week 8 in patients with GAD. Treatment response is considered as ≥ 50% decrease of the Hamilton Anxiety Rating Scale (HARS) total score from baseline.
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding pilot study to assess the efficacy and safety of CD-008-0045 in patients with Generalized Anxiety Disorder (GAD). Each patient will participate in the study for the period of approximately 10 weeks: Screening and Run-in period: 1 week; Study Treatment period: 8 weeks; Follow-up period: 1 week.

Detailed description: The study drug CD-008-0045 has a multi-targeted activity, i.e., able to inhibit adrenergic, dopamine, serotonin, and histamine receptors, thus allowing to assume its wide therapeutic potential. At Screening, the patients who meet the inclusion/exclusion criteria will be included into one-week single-blind Placebo Run-in period. At Week 0 the patients will be randomized to receive CD-008-0045 60 mg daily, CD-008-0045 40 mg daily or Placebo for 8 weeks. The potential withdrawal syndrome will be assessed during one-week Follow-up Period.

Eligibility criteria: Inclusion criteria:

1. Signed Informed Consent Form;
2. Age 18 years and older;
3. Generalized anxiety disorder diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria and International Classification of Diseases (ICD-10);
4. Hamilton Anxiety Rating Scale (HARS) values at Screening and on Randomization Visit (Week 0): Total score ≥ 20; Item 1 (Anxious mood) and Item 2 (Tension) scores ≥ 2;
5. The CGI-S score ≥ 4 (moderate severity and higher) at Screening and on Randomization visit (Week 0);
6. Consent of patients to use adequate contraception methods throughout the study. Adequate contraception methods include:

   * Condoms with spermicide for males;
   * For females (at their discretion):

     * oral contraceptives
     * condoms with spermicide (for the partner)
     * diaphragm with spermicide
     * cervical cap with spermicide
     * intrauterine device
7. Ability to comply with all Study Protocol requirements.

Exclusion criteria:

1. Pregnant or lactating women, or women planning to get pregnant during the clinical study; women of childbearing potential (including those without history of surgical sterilization and women with \<2 years of post-menopause) not using adequate contraception methods;
2. Item 1 (Depressed mood) of the Hamilton Depression Rating Scale (HAMD) score ≥ 2;
3. Hamilton Depression Rating Scale (HAMD) total score \> 13;
4. Confirmed diagnosis of depressive episode, recurrent depressive disorder, bipolar affective disorder in history or at Screening;
5. Confirmed diagnosis of schizophrenia in history or at Screening;
6. Confirmed diagnosis of panic disorder in history or at Screening;
7. Phobic anxiety disorders (agoraphobia, social phobia, unspecified phobic anxiety disorder) in history or at Screening;
8. Disorders of personality or behavior in history or at Screening;
9. Post-traumatic stress disorder diagnosed within 12 months prior to Screening;
10. Eating disorders diagnosed within 12 months prior to Screening;
11. Somatoform disorders in history or at Screening;
12. Obsessive-compulsive disorder in history or at Screening;
13. Epilepsy, seizures, head trauma with loss of consciousness, tumors, inflammatory, or demyelinating diseases of the central nervous system, stroke in history;
14. Pheochromocytoma;
15. Malignancies diagnosed within the last 5 years (except for the cured basal cell carcinoma);
16. Significant cardiovascular diseases diagnosed at present or within 12 months prior to Screening, including: Chronic heart failure, class III or IV (according to New York Heart Association classification); severe arrhythmia requiring treatment with class Ia, Ib, Ic, or III antiarrhythmic drugs; unstable angina; myocardial infarction; heart and coronary artery surgery; significant valvular heart disease; uncontrolled hypertension with systolic blood pressure \> 180 mm Hg and diastolic blood pressure \> 110 mm Hg; pulmonary embolism or deep vein thrombosis;
17. Nephrotic syndrome; moderate to severe chronic renal failure or significant renal diseases with creatinine level \>1.5 mg/dL (132 μM/L) in males and \> 1.4 mg/dL (123 μM/L) in females, or glomerular filtration rate (GFR) \< 60 mL/min;
18. HIV, hepatitis B or C, liver cirrhosis in history; AST, ALT, or serum alkaline phosphatase ≥ 2.5 times above the upper limit of normal; total bilirubin level ≥ 2 times above the upper limit of normal at Screening;
19. Significant dysfunctions of the thyroid gland in decompensation stage;
20. Anemia (hemoglobin level ≤ 105 g/L in females or ≤ 115 g/L in males); significant blood loss, or collection of at least one volumetric unit of donated blood (≥ 500 ml), or blood transfusion within 12 weeks prior to Screening;
21. Any uncontrolled concomitant somatic disease, including that with a stable treatment regimen;
22. Drugs administered for generalized anxiety disorder, starting from Screening and throughout the study, including antidepressants, Pregabalin, benzodiazepines, antipsychotics;
23. Fluoxetine use within 21 days prior to Screening and throughout the study;
24. Known allergy, hypersensitivity or contraindications to CD-008-0045;
25. Electroconvulsive therapy within 3 months prior to Screening;
26. Psychotherapy within 3 months prior to Screening and/or at the time of enrollment into the study;
27. Use of prohibited drug therapy from the moment of Screening and throughout the study;
28. Administration of any study drug or participation in another clinical study within 3 months prior to Screening (except for cases when the patient was not administered the study drug during the study);
29. Addiction to tranquilizers or psychoactive substance abuse, including alcohol (history of episodic use is acceptable);
30. Inability to read or right; unwillingness to understand and comply with the Protocol procedures; non-compliance with drug dosage regimen or procedures which, in the Investigator's opinion, may affect the study results or the patient's safety and prevent the patient's participation in the study; any other concomitant diseases or severe mental disorders, which make the patient ineligible for participation in the study, limit the legal basis for Informed Consent procedure, or may affect the patient's ability to participate in the study.

Primary outcomes:
measure: Frequency of treatment response
timeFrame: Baseline to Week 8
Secondary outcomes:
measure: Change of the HARS total score
timeFrame: Baseline to Week 8, Week 8 to Week 9
measure: Change in the score sum of the mental and somatic anxiety subscales of HARS
timeFrame: Baseline to Week 8
measure: Change of scores in items 1 (Anxious mood) and 2 (Tension) of HARS
timeFrame: Baseline to Week 8
measure: Change of the sum of Hamilton Depression Rating Scale (HAM-D) scores
timeFrame: Baseline to Week 8, Week 8 to Week 9
measure: Change in the Clinical Global Impression - Severity Scale (CGI-S)
timeFrame: Baseline to Week 8, Week 8 to Week 9
measure: Clinical Global Impression - Improvement Scale (CGI-I)
timeFrame: Week 4, Week 8, Week 9
measure: Change of daytime somnolence level based on Visual Analogue Scale (VAS)
timeFrame: Baseline to Week 8, Week 8 to Week 9
measure: CD-008-0045 concentration prior to the next drug administration (Ctrough)
timeFrame: Week 4, Week 8
measure: M1 concentration prior to the next drug administration (Ctrough)
timeFrame: Week 4, Week 8
measure: CD-008-0045 concentration 1 hour post drug administration (Cmax)
timeFrame: Week 4, Week 8
measure: M1 concentration 1 hour post drug administration (Cmax)
timeFrame: Week 4, Week 8
measure: CYP2D6 polymorphism
timeFrame: Week 4
measure: Incidence of adverse events (AE) and serious adverse events (SAE)
timeFrame: Baseline to Week 9
Other outcomes:
Locations:
city: Stavropol
country: Russian Federation
facility: Clinical Center LLC "Center for Psychotherapy "Support"
state: Stavropol Region
city: Moscow
country: Russian Federation
facility: "Research Center for Mental Health" Scientific Institution
city: Moscow
country: Russian Federation
facility: Clinical Center LLC "University Headache Clinic"
city: Moscow
country: Russian Federation
facility: Moscow Research Institute of Psychiatry "National Medical Research Center for Psychiatry and Narcology named after V.P. Serbsky"
city: Nizhny Novgorod
country: Russian Federation
facility: Nizhny Novgorod Clinical Psychiatric Hospital No.1
city: Rostov-on-Don
country: Russian Federation
facility: Clinical Center LLC "TREATMENT AND REHABILITATION RESEARCH CENTER "PHOENIX "
city: Ryazan
country: Russian Federation
facility: Ryazan Medical University, Department of Psychiatry
city: Saint Petersburg
country: Russian Federation
facility: Clinical Center LLC "Doctor SAN"
city: Saint Petersburg
country: Russian Federation
facility: Clinical Center LLC "Dynasty"
city: Saint Petersburg
country: Russian Federation
facility: Leningrad Regional Psychoneurological Dispensary
city: Saint Petersburg
country: Russian Federation
facility: St. Petersburg "Psychoneurological dispensary #5"
city: Voronezh
country: Russian Federation
facility: Clinical Center LLC "LION-MED"
city: Voronezh
country: Russian Federation
facility: Clinical Center LLC "Medical practice"
city: Yaroslavl
country: Russian Federation
facility: Yaroslavl Regional Psychiatric Hospital
city: Yekaterinburg
country: Russian Federation
facility: Clinical Center JSC "Medical Technologies"
Study officials:
affiliation: "Research Center for Mental Health" Scientific Institution
name: Margarita A Morozova, MD,PhD,Prof
role: PRINCIPAL_INVESTIGATOR
References: